| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794980 | Ophthalmology Retina | 2017 | 6 Pages |
Abstract
Industry payments to ophthalmologists who perform intravitreal injections were associated with higher odds of ranibizumab and aflibercept use, and lower odds of bevacizumab use. These findings reflect an association, not a cause-and-effect relationship.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Michael A. MD, David O. MS, Jay C. MD,